Grufity logoGrufity logo

Pacific Biosciences of California Inc Stock Research

PACB

9.32USD-0.29(-3.02%)Market Closed

Market Summary

USD9.32-0.29
Market Closed
-3.02%

PACB Alerts

PACB Stock Price

PACB RSI Chart

PACB Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

-6.41

Price/Sales (Trailing)

15.69

EV/EBITDA

-5.82

Price/Free Cashflow

-7.19

PACB Price/Sales (Trailing)

PACB Profitability

Operating Margin

38.22%

EBT Margin

-244.92%

Return on Equity

-55.83%

Return on Assets

-17.78%

Free Cashflow Yield

-13.9%

PACB Fundamentals

PACB Revenue

Revenue (TTM)

128.3M

Revenue Y/Y

-24.06%

Revenue Q/Q

-15.34%

PACB Earnings

Earnings (TTM)

-314.2M

Earnings Y/Y

-21.72%

Earnings Q/Q

-9.63%

Price Action

52 Week Range

3.8514.20
(Low)(High)

Last 7 days

11.5%

Last 30 days

6.3%

Last 90 days

16.2%

Trailing 12 Months

0.9%

PACB Financial Health

Current Ratio

3.24

PACB Investor Care

Shares Dilution (1Y)

2.50%

Diluted EPS (TTM)

-1.4

Peers (Alternatives to Pacific Biosciences of California)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
39.3B
6.8B
-5.76% -1.62%
31.3
5.73
8.37% 3.64%
34.4B
4.6B
10.80% -36.26%
-7.81
7.51
1.28% -677.95%
32.8B
3.9B
3.74% 6.71%
37.59
8.37
5.43% 13.46%
17.9B
3.0B
-3.60% -7.13%
25.24
6.01
6.68% 2.15%
16.2B
3.3B
2.29% -27.60%
28.4
4.88
-34.64% -39.65%
MID-CAP
SMALL-CAP
2.0B
128.3M
6.27% 0.87%
-6.41
15.69
-1.69% -73.40%
1.1B
185.3M
4.81% -31.55%
-5.67
6.12
20.06% 3.42%
401.5M
105.5M
-5.95% -61.12%
-4.15
3.8
-4.55% -67.63%
401.3M
127.3M
-3.95% -71.99%
-2.52
3.15
-12.28% -38.43%
323.9M
27.8M
-13.39% -53.59%
-2.44
11.65
54.62% -83.06%
250.7M
138.6M
-19.03% -80.42%
-7.46
1.81
32.30% -57.86%
126.7M
113.3M
13.22% -43.77%
-13.31
1.12
-4.68% -3204.17%
125.6M
65.0M
-11.53% -66.71%
-1.11
1.93
-23.92% -73.73%
56.3M
54.1M
-9.78% -51.18%
521
1.04
21.80% -72.38%

Financials for Pacific Biosciences of California

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-6.3%128,304,000136,970,000139,546,000134,689,000130,513,000
Cost Of Revenue3.9%79,269,00076,309,00077,068,00074,651,00071,653,000
Gross Profit-19.2%49,035,00060,661,00062,478,00060,038,00058,860,000
Operating Expenses3.1%356,231,000345,449,000347,122,000314,286,000269,295,000
  S&GA Expenses5.0%160,854,000153,171,000147,982,000137,790,000124,124,000
  R&D Expenses0.0%193,000,000192,953,000173,369,000145,287,000112,899,000
EBITDA-8.8%-290,078,000-266,535,000-252,572,000--
EBITDA Margin-16.2%-2.26-1.95-1.88--
Earnings Before Taxes-8.3%-314,248,000-290,250,000-274,872,000--
EBT Margin-15.6%-2.45-2.12-2.04--
Interest Expenses1.2%14,690,00014,521,00014,530,00014,438,00012,530,000
Net Income-5.0%-314,248,000-299,193,000-205,680,000-175,287,000-181,223,000
Net Income Margin-12.1%-2.45-2.18-1.47-1.30-
Free Cahsflow-12.4%-279,961,000-249,041,000-223,574,000-176,273,000-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-2.9%1,7671,8191,8761,9372,007
  Current Assets-6.8%8529149701,0291,101
    Cash Equivalents6.8%325304310429461
  Inventory15.8%50.0043.0036.0030.0025.00
  Net PPE6.2%42.0039.0038.0036.0033.00
  Goodwill0%410410410410410
Liabilities1.0%1,2041,1921,1941,2021,216
  Current Liabilities222.5%26382.0084.0061.0072.00
Shareholder's Equity-10.2%563627682735791
  Retained Earnings-5.8%-1,532-1,447-1,370-1,299-1,218
  Additional Paid-In Capital0.9%2,1002,0812,0582,0382,010
Shares Outstanding0.3%227226225224221
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-12.3%-263-234-211-167-111
  Share Based Compensation-1.2%79.0080.0089.0086.0073.00
Cashflow From Investing14.4%116101-244-644-678
Cashflow From Financing-5.0%10.0010.003073091,170

Risks for PACB

What is the probability of a big loss on PACB?

100%


Probability that Pacific Biosciences of California stock will be more than 20% underwater in next one year

90%


Probability that Pacific Biosciences of California stock will be more than 30% underwater in next one year.

72.3%


Probability that Pacific Biosciences of California stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PACB drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Pacific Biosciences of California was unfortunately bought at previous high price.

Drawdowns

Returns for PACB

Cumulative Returns on PACB

14.1%


10-Year Cumulative Returns

2.3%


7-Year Cumulative Returns

33.7%


5-Year Cumulative Returns

41.6%


3-Year Cumulative Returns

What are the long-term rolling returns for PACB?

FIve years rolling returns for Pacific Biosciences of California.

Annualized Returns

Which funds bought or sold PACB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-23
MetLife Investment Management, LLC
unchanged
-
279,915
964,087
0.01%
2023-03-17
American Portfolios Advisors
reduced
-1.48
38,948
171,486
0.01%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-0.04
54,862
187,862
-%
2023-03-06
Rockefeller Capital Management L.P.
added
107
6,000
8,000
-%
2023-02-28
Voya Investment Management LLC
unchanged
-
205,282
708,282
-%
2023-02-28
Orin Green Financial, LLC
unchanged
-
28,160
98,160
0.06%
2023-02-27
Parallax Volatility Advisers, L.P.
reduced
-99.45
-1,046,880
8,123
-%
2023-02-24
NATIXIS
sold off
-100
-2,300,000
-
-%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
new
-
650
650
-%
2023-02-21
MACQUARIE GROUP LTD
reduced
-0.27
9,458,000
32,822,000
0.04%

1–10 of 39

Latest Funds Activity

Are funds buying PACB calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own PACB
No. of Funds

Pacific Biosciences of California News

Marketscreener.com

PacBio and Corteva Agriscience Enable Groundbreaking Plant and Microbial Long-Read Sequencing Workflow on Revio System.

Marketscreener.com,
24 minutes ago

Stocks Register

Marketing Sentinel

Schedule 13G FIlings of Pacific Biosciences of California

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital international investors
2.7%
6,099,681
SC 13G/A
Feb 13, 2023
madrone capital partners, llc
7.3%
16,415,933
SC 13G/A
Feb 10, 2023
nikko asset management americas, inc.
6.26%
14,166,193
SC 13G/A
Feb 10, 2023
ark investment management llc
11.36%
25,691,681
SC 13G/A
Feb 10, 2023
jackson square partners, llc
6.64%
15,005,177
SC 13G/A
Feb 09, 2023
vanguard group inc
8.97%
20,279,035
SC 13G/A
Feb 03, 2023
blackrock inc.
8.2%
18,534,459
SC 13G/A
Feb 03, 2023
sumitomo mitsui trust holdings, inc.
6.26%
14,166,193
SC 13G/A
Jun 01, 2022
madrone capital partners, llc
6.0%
13,415,933
SC 13G
Feb 14, 2022
nikko asset management americas, inc.
5.40%
11,915,025
SC 13G

PACB Fair Value

Pacific Biosciences of California fair value in different scenarios

The table shows the Fair Value estimates for Pacific Biosciences of California for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

0.47

-94.96%

0.50

-94.64%

0.57

-93.88%

0.69

-92.60%

0.86

-90.77%
Current Inflation

0.47

-94.96%

0.50

-94.64%

0.56

-93.99%

0.66

-92.92%

0.81

-91.31%
Very High Inflation

0.47

-94.96%

0.49

-94.74%

0.54

-94.21%

0.63

-93.24%

0.75

-91.95%

Historical Pacific Biosciences of California Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Pacific Biosciences of California

View All Filings
Date Filed Form Type Document
Mar 27, 2023
PRE 14A
PRE 14A
Mar 17, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Feb 28, 2023
10-K
Annual Report
Feb 28, 2023
S-8
Employee Benefits Plan
Feb 22, 2023
4
Insider Trading

Latest Insider Trading transactions for PACB

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-15
Ericson William W.
sold
-67,114
8.9
-7,541
-
2023-03-15
Ericson William W.
acquired
63,500
2.54
25,000
-
2023-03-03
Kim Susan G.
sold
-47,892
9.493
-5,045
see remarks
2023-03-03
Farmer Michele
sold
-29,931
9.493
-3,153
see remarks
2023-03-03
Van Oene Mark
sold
-59,502
9.493
-6,268
see remarks
2023-03-03
HENRY CHRISTIAN O
sold
-130,709
9.493
-13,769
see remarks
2023-03-02
HENRY CHRISTIAN O
acquired
-
-
594,687
see remarks
2023-03-02
Van Oene Mark
acquired
-
-
328,500
see remarks
2023-03-02
Kim Susan G.
acquired
-
-
164,200
see remarks
2023-03-02
Eidel Jeff
acquired
-
-
164,200
see remarks

1–10 of 50

Christian O. Henry
730
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

PACB Income Statement

2022-12-31
Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($)
shares in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue:   
Total revenue$ 128,304,000$ 130,513,000$ 78,893,000
Cost of Revenue:   
Amortization of intangible assets733,000306,000 
Loss on purchase commitment3,705,000  
Total cost of revenue79,269,00071,653,00046,327,000
Gross profit49,035,00058,860,00032,566,000
Operating Expense:   
Research and development193,000,000112,899,00064,152,000
Sales, general and administrative160,854,000124,124,00072,799,000
Merger-related expenses 31,129,000 
Change in fair value of contingent consideration2,377,0001,143,000 
Total operating expense356,231,000269,295,000136,951,000
Operating loss(307,196,000)(210,435,000)(104,385,000)
Gain from Reverse Termination Fee from Illumina  98,000,000
(Loss)/Gain from Continuation Advances from Illumina (52,000,000)34,000,000
Interest expense(14,690,000)(12,530,000)(267,000)
Other income, net7,638,00093,0002,055,000
(Loss) income before benefit from income taxes(314,248,000)(274,872,000)29,403,000
Benefit from income taxes (93,649,000) 
Net (loss) income(314,248,000)(181,223,000)29,403,000
Other comprehensive (loss) income:   
Unrealized (loss) gain on investments(3,678,000)(1,172,000)80,000
Comprehensive (loss) income:$ (317,926,000)$ (182,395,000)$ 29,483,000
Net (loss) income per share:   
Basic$ (1.40)$ (0.89)$ 0.18
Diluted$ (1.40)$ (0.89)$ 0.17
Weighted average shares outstanding used in calculating net (loss) income per share:   
Basic224,550204,136165,187
Diluted224,550204,136174,970
Product [Member]   
Revenue:   
Total revenue$ 108,699,000$ 113,505,000$ 65,424,000
Cost of Revenue:   
Cost of product revenue60,932,00056,358,00035,424,000
Service and Other [Member]   
Revenue:   
Total revenue19,605,00017,008,00013,469,000
Cost of Revenue:   
Cost of service and other revenue$ 13,899,000$ 14,989,000$ 10,903,000

PACB Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 325,089$ 460,725
Investments447,229583,675
Accounts receivable, net18,78624,241
Inventory, net50,38124,599
Prepaid expenses and other current assets10,2897,394
Short-term restricted cash300500
Total current assets852,0741,101,134
Property and equipment, net41,58032,504
Operating lease right-of-use assets, net39,76346,617
Long-term restricted cash2,9224,592
Intangible assets, net410,245410,979
Goodwill409,974409,974
Other long-term assets10,5281,170
Total assets1,767,0862,006,970
Current liabilities  
Accounts payable12,02811,002
Accrued expenses32,59636,261
Deferred revenue, current30,49810,977
Operating lease liabilities, current8,8867,710
Other liabilities, current7,2335,759
Contingent consideration liability, current172,094 
Total current liabilities263,33571,709
Deferred revenue, non-current1,79425,049
Contingent consideration liability, non-current 169,717
Operating lease liabilities, non-current41,07049,970
Convertible senior notes, net, non-current896,683896,067
Other liabilities, non-current1,3003,471
Total liabilities1,204,1821,215,983
Commitments and contingencies
Stockholders' equity  
Preferred stock, $0.001 par value: Authorized 50,000 shares; No shares issued or outstanding
Common stock, $0.001 par value: Authorized 1,000,000 shares; issued and outstanding 226,505 and 220,978 shares at December 31, 2022 and December 31, 2021, respectively227221
Additional paid-in capital2,099,7822,009,945
Accumulated other comprehensive loss(4,765)(1,087)
Accumulated deficit(1,532,340)(1,218,092)
Total stockholders' equity562,904790,987
Total liabilities and stockholders' equity$ 1,767,086$ 2,006,970